Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 52-Week High – What’s Next?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) hit a new 52-week high on Tuesday . The stock traded as high as $16.20 and last traded at $14.4550, with a volume of 2219594 shares traded. The stock had previously closed at $13.17.

Analysts Set New Price Targets

AUPH has been the subject of several analyst reports. Royal Bank Of Canada upped their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Aurinia Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.91 billion, a P/E ratio of 33.83 and a beta of 1.25. The company has a fifty day moving average of $12.10 and a two-hundred day moving average of $10.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, November 6th. The biotechnology company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. On average, equities analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares during the last quarter. MAI Capital Management bought a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $39,000. DekaBank Deutsche Girozentrale bought a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $60,000. Xponance Inc. bought a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $82,000. Finally, Kazazian Asset Management LLC bought a new position in Aurinia Pharmaceuticals in the 1st quarter worth approximately $84,000. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.